attachments may be formatted as WordPerfect 5.0, 5.1/5.2, 6.0/6.1, or ASCII files.

Information can also be obtained by calling 1–800–35–NIOSH or by the Internet NOISH Homepage: http:/www.cdc.gov/noish/homepage.html.

Dated: May 14, 1996.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–12557 Filed 5–17–96; 8:45 am]

BILLING CODE 4160–19–M

Food and Drug Administration

[Docket No. 96F–0145]

Albright & Wilson, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Albright & Wilson, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of tetrakis(hydroxymethyl)phosphonium sulfate as a slimicide for use in the manufacture of paper and paperboard intended to contact food.

DATES: Written comments on the petitioner's environmental assessment by June 19, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204–0002, 202–418–3080.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4472) has been filed by Albright & Wilson, Ltd., c/o Delta Analytical Corp., 7910 Woodmont Ave., suite 1000, Bethesda, MD 20814. The petition proposes to amend the food additive regulations in § 176.300 *Slimicides* (21 CFR 176.300) to provide for the safe use of tetrakis(hydroxymethyl)phosphonium sulfate as a slimicide in the manufacture of paper and paperboard intended to contact food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before June 19, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: April 30, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–12568 File6d 5–17–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0152]

Witco Corp.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to future filing, of a food additive petition (FAP 3B4348), filed by Witco Corp. proposing that the food additive regulations be amended to provide for the safe use of decanedioic acid, polymer with 1,2-ethanediamine, (Z,Z)-9,12-octadecadienoic acid dimer and 4,4′-(1,3-propaneidyl) bis (piperidine) as a polymer coating onaluminum foil, polyolefin film, and paper and paperboard and as an adhesive, for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of May 19, 1993 (58 FR 29231), FDA announced that a food additive petition (FAP 3B4348) had been filed by Witco Corp., 5777 Frantz Rd., P.O. Box 646, Dublin, OH 43017. The petition proposed to amend the food additive regulations to provide for the safe use of decanedioic acid, polymer with 1,2-ethanediamine, (Z,Z)-9,12-octadecadienoic acid dimer and 4,4′-(1,3-propaneidyl) bis (piperidine) as a polymer coating on aluminum foil, polyolefin film, and paper and paperboard and as an adhesive, for use in contact with food. Witco Corp. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: April 30, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–12567 Filed 5–17–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0151]

SmithKline Beecham Pharmaceuticals; Withdrawal of Approval of a New Drug Application for Selacryn® Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for Selacryn® (ticrynafen) Tablets held by SmithKline Beecham Pharmaceuticals (Smithkline). SmithKline requested that the NDA be withdrawn because the product is no longer being marketed. SmithKline also waived its opportunity for a hearing.

EFFECTIVE DATE: May 20, 1996.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: By letter dated June 30, 1994, SmithKline, Four Falls Corp. Center, Route 23 and Woodmont Ave., P.O. Box 1510, FF0410, King of Prussia, PA 19406, requested that FDA withdraw NDA 18–103 for Selacryn® (ticrynafen) Tablets, stating that the company discontinued